A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children ≥28 Days and ≤3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen; Janssen Pharmaceutical KK; Janssen Research & Development
- 26 Nov 2019 Planned End Date changed from 30 Nov 2020 to 20 Dec 2021.
- 07 Aug 2019 Planned End Date changed from 30 Nov 2021 to 30 Nov 2020.
- 04 Aug 2019 Planned number of patients changed from 372 to 444.